Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients Data Confirm SIGMAR1 and COMT as Genetic Biomarkers of Response to...